Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda And Cell Genesys Ink $270 Million Development Deal for GVAX Immunotherapy

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Japan-based Takeda and San Francisco-based Cell Genesys formed a global development alliance for Cell Genesys's lead product GVAX immunotherapy for prostate cancer, currently in Phase III trials
Advertisement

Related Content

Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Advertisement
UsernamePublicRestriction

Register

SC068231

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel